Peptide News Digest

Sangamo Files Chapter 11 with Lilly $50M Stalking-Horse Bid, 18 Bioethics Experts Call Retatrutide Compassionate Use Unusual, ONVAX-01 Peptide Nanovaccine in Pancreatic Cancer, HIMS June 25% Rally on Novo 'Voluminous Partner' Label, Medicare GLP-1 Bridge 5 Days Out, Brain Peptides Alzheimer's Review

Sangamo Chapter 11 + Lilly $50M; 18 bioethics experts on retatrutide; ONVAX-01; HIMS rally; Medicare GLP-1 Bridge July 1; brain peptides Alzheimer's review.

7 stories · Covering industry, regulatory, clinical-trials, research

Editor's Note

Friday closed the week with two stories that crystallized the two ends of peptide capital flow. Sangamo Therapeutics filed Chapter 11 in Delaware on Monday June 23 with Eli Lilly as stalking-horse bidder at a $50 million cash floor plus assumption of certain liabilities for the capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas takes the Fabry disease asset isaralgagene civaparvovec separately. Sangamo cut 51 people (40% of staff) the same day. The company's three-decade gene-editing arc ends with two stalking-horse bids and a Nasdaq delisting that preceded the filing by a month. On the access-equity track, STAT News reported that 18 bioethics experts, obesity clinicians, and current and former government health officials told the outlet the retatrutide compassionate-use application 'struck them as unusual,' questioning why Lilly would grant single-patient access for a condition as widespread as obesity. That bioethics-community pushback runs parallel to the political theater (Hassan letter, Lieu press conference, White House counterattacks) and may end up the more durable critique. The week also produced one fresh clinical-trial start (Phase 1/2 ONVAX-01 personalized peptide nanovaccine plus anti-PD-1 antibody and chemotherapy in advanced pancreatic cancer) and a Cosmetics Business feature surveying eight new peptide-anchored beauty launches across Shiseido, YSE, and the K-beauty PDRN-peptide-exosome stack.

Industry

Sangamo Therapeutics Files Chapter 11 in Delaware Bankruptcy Court (June 23) with Eli Lilly $50M Stalking-Horse Bid for Capsid, Zinc Finger, MINT, and Prion Disease ST-506 Programs; Astellas Takes Fabry Disease Asset Isaralgagene Civaparvovec; 51 Employees (40% of Staff) Laid Off the Same Day

Gene-editing pioneer Sangamo Therapeutics filed a voluntary Chapter 11 petition in the US Bankruptcy Court for the District of Delaware on Monday June 23, 2026, after disclosing only $27.6 million in cash as of March 31 and a May 2026 Nasdaq delisting for minimum-bid-price non-compliance. Two simultaneous asset purchase agreements established the floor. Eli Lilly is the stalking-horse bidder at $50 million cash plus assumption of certain liabilities for Sangamo's capsid delivery platform, zinc finger platform, modular integrase (MINT) platform, and prion disease program ST-506. Astellas Pharma takes the Fabry disease asset isaralgagene civaparvovec (ST-920) under a separate agreement. The Lilly bid covers the assets most relevant to the peptide-adjacent neurology pipeline, with prion protein biology offering platform optionality for Lilly's broader neurodegeneration program. Both agreements remain subject to higher-or-better offers under standard Section 363 sale procedures. Sangamo simultaneously cut 51 employees, approximately 40% of its remaining workforce, with the remainder retained through the auction and sale process. The bankruptcy closes a 30-year arc that began as the zinc-finger nuclease pioneer through gene editing's commercial first wave, and underscores that gene-editing platform capital is now consolidating into large-pharma hands.

#sangamo-bankruptcy #eli-lilly #astellas #stalking-horse-bid #chapter-11 #zinc-finger #prion-disease #st-506 #isaralgagene-civaparvovec #gene-editing-consolidation
Regulatory

STAT News (June 23): 18 Bioethics Experts, Obesity Clinicians, and Current and Former Government Health Officials Tell STAT Retatrutide Compassionate-Use Application 'Struck Them as Unusual'; Bioethics-Community Pushback Runs Parallel to Political Theater Around 79-Year-Old Patient

In addition to the political escalation (Senator Hassan's June 25 letter to RFK Jr.; Rep. Ted Lieu's June 24 terminal-illness press conference; White House counterattacks against STAT reporter Lizzy Lawrence and Lieu), STAT News reported that 18 bioethics experts, obesity-medicine clinicians, and current and former US government health officials told the outlet that Eli Lilly's decision to grant compassionate-use access to retatrutide for a single 79-year-old patient with refractory obesity, obstructive sleep apnea, and pulmonary hypertension 'struck them as unusual.' The core question raised by the bioethics community: why Lilly would offer compassionate use for a single patient when obesity is a population-scale condition affecting more than 100 million Americans, when expanded-access programs are typically structured around treatment INDs or intermediate-size protocols for broader access, and when the standard pathway for obesity-drug access is trial enrollment (TRIUMPH-2 obesity+T2D and TRIUMPH-3 obesity+CVD remain open). Jamy Ard (chief science officer, Advocate Health) said compassionate use is typically reserved for terminal illness. The bioethics critique is separate from the Trump-recipient speculation and is likely the more durable framing of the case as it moves through congressional oversight.

#retatrutide #compassionate-use #bioethics #eli-lilly #access-equity #stat-news #obesity-medicine #expanded-access
Clinical Trials

ONVAX-01 Personalized Peptide Nanovaccine Plus Anti-PD-1 Antibody and Chemotherapy Phase 1/2 Trial in Advanced Pancreatic Cancer Recruiting (NCT07637786, Late June 2026 Listing) — Targets KRAS Neoantigens in a Tumor with 90% KRAS-Mutation Prevalence

A Phase 1/2 study (NCT07637786) of ONVAX-01, a personalized peptide nanovaccine, in combination with an anti-PD-1 antibody and standard-of-care chemotherapy in patients with advanced pancreatic cancer began recruiting in late June 2026. The trial design has participants receive doses of the nanovaccine along with intravenous infusions of an anti-PD-1 checkpoint inhibitor plus chemotherapy, with serial imaging and blood-marker monitoring for tumor response. ONVAX-01 sits in the same broad therapeutic space as Elicio Therapeutics' ELI-002 7P (which missed its Phase 2 AMPLIFY-7P primary disease-free survival endpoint on June 15) but with a different delivery vehicle (nanoparticle self-assembly versus amphiphile-modified CpG oligonucleotide adjuvant). KRAS mutations drive approximately 90% of pancreatic ductal adenocarcinoma cases and 50% of colorectal cancers, making KRAS-targeting peptide vaccines one of the highest-impact unmet targets in solid-tumor oncology. The peptide nanovaccine modality has roots in 2022 case-report literature on neoantigen nanovaccine immunotherapy in advanced pancreatic cancer and broader nanovaccine work using DP7-C antimicrobial peptide as carrier-plus-adjuvant.

#onvax-01 #peptide-nanovaccine #pancreatic-cancer #kras #anti-pd-1 #personalized-cancer-vaccine #clinicaltrials-gov #neoantigen
Industry

Hims & Hers (HIMS) Stock Up 25% in June on Novo Nordisk 'Voluminous Telehealth Partner' Label; Leerink Reiterates Market Perform Pre-PCAC July 23-24 Meeting; CEO Andrew Dudum Confirms Oura Ring Integration 'Coming Soon'

Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.

#hims-hers #stock-rally #novo-nordisk #leerink #barclays #pcac #oura-ring #telehealth
Regulatory

Medicare GLP-1 Bridge Launches Wednesday July 1 (5 Days Out): Humana as Single Central Processor, Prior-Authorization Fax Line Goes Live July 1, Prescribers Do Not Need Medicare Enrollment, $50/Month for Foundayo, Wegovy (Injection and Tablets), and Zepbound KwikPen Through December 31, 2027

The Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge demonstration launches Wednesday July 1, 2026, five days from this digest's publication, providing eligible Medicare Part D beneficiaries with $50/month access to Foundayo (orforglipron), Wegovy (injection and 1.5/4/9/25 mg tablets), and Zepbound (KwikPen) for chronic weight management through December 31, 2027. Humana is the single central processor for prior authorization, claims adjudication, and pharmacy payment, operating outside of the standard Part D benefit's coverage and payment flow (Part D sponsors do not carry risk for eligible GLP-1 drugs under the Bridge). Two procedural details for prescribers: Medicare enrollment is not required to write a prescription or submit a prior-authorization request under the Bridge (the provider just cannot be on the Preclusion List), and prior-authorization requests will not be accepted or processed before July 1, when the prior-authorization form will be updated to include the fax submission number. Eligibility runs through three BMI tiers: BMI ≥35 with no additional requirement; BMI ≥30 with comorbid heart failure, uncontrolled hypertension, or chronic kidney disease; or BMI ≥27 with prediabetes, prior MI, prior stroke, or peripheral artery disease. The Bridge bridges to the broader BALANCE Model launching January 2027 in Medicare Part D.

#medicare-glp-1-bridge #cms #humana #july-1-launch #prior-authorization #balance-model #foundayo #wegovy #zepbound
Research

Cell and Tissue Research 2026 Review: Brain Peptides in Alzheimer's Disease, Pathogenic Amyloid-Beta Oligomers and Tau-Derived Fragments Versus Neuroprotective NPY, VIP, PACAP; Aggregation Inhibitors and Receptor-Selective Neuropeptide Analogues Define the 2026 Therapeutic Frontier

A 2026 review published in Cell and Tissue Research (Springer Nature) synthesized the current understanding of brain peptides in Alzheimer's disease pathophysiology and therapeutic development. The review's central organizing distinction is between pathogenic peptide species (amyloid-β oligomers, tau-derived fragments) that drive neuronal dysfunction and endogenous neuropeptides that exert neuroprotective effects: neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), and pituitary adenylate cyclase-activating peptide (PACAP) are the three best-characterized protective classes. Adjacent April 2026 IJMS review covers the same neuropeptide neuroprotection thesis with broader Parkinson's-disease applicability. Advances in peptide chemistry are enabling two distinct therapeutic strategies: aggregation inhibitors that prevent amyloid-β oligomerization, and receptor-selective neuropeptide analogues that recapitulate endogenous NPY/VIP/PACAP signaling with improved blood-brain-barrier penetration. The peptide-neurodegeneration thread runs parallel to the BioArctic-Lilly $800 million BrainTransporter pact (June 23, peptide-delivery focus), Insilico-SK Biopharm $2.5B AI-neuroimmune deal (June 22 BIO 2026 opening), and the NVG-291 PTPσ inhibitor that NervGen is preparing for Phase 3 in chronic SCI mid-2026.

#alzheimers #neuropeptides #amyloid-beta #tau #npy #vip #pacap #neurodegeneration #blood-brain-barrier
Industry

Cosmetics Business Feature (June 2026): Eight New Peptide-Anchored Beauty Launches Tracked: Shiseido Ultimune Power Infusing Oil, YSE Beauty Xtreme Glow Dewy Peptide Plumping Serum ($68), K-Beauty PDRN-Peptide-Exosome Stack Defining 2026 Skincare

Cosmetics Business published an industry feature in June 2026 cataloging eight peptide-anchored beauty launches during the year's first half, framing 2026 as the year topical peptide skincare crossed from prestige-only to mass-market shelves. Tracked launches include Shiseido's refreshed Ultimune Power Infusing Oil (a serum-format extension of the brand's signature resilience line), YSE Beauty's Xtreme Glow Dewy Peptide Plumping Serum ($68, the company's best first-day and first-week launch by units), and adjacent product categories anchored on PDRN (polydeoxyribonucleotide), exosomes, and acetyl-hexapeptide and palmitoyl-tripeptide blends. AOL and Glossy parallel coverage flagged the K-beauty PDRN-peptide-exosome stack as the defining ingredient combination for 2026 (matched against retinol on efficacy claims, against snail mucin on heritage positioning). The cosmetic-peptide commercial wave runs alongside the regulatory wave: the FDA peptide categories under PCAC review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) include several with cosmetic-adjacent claims, and the Moes Group / CKYN / GELITA / Italgel manufacturing pipeline tracked in June digests anchors the supply side.

#cosmetic-peptides #shiseido #yse-beauty #k-beauty #pdrn #exosomes #peptide-skincare #consumer-trend